Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Nov 1, 2023 · 10-Q · 32 days after period end · 0000950170-23-057414
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $309.32M | $207.77M | $166.91M | $121.43M |
| Net Income | -$40.94M | -$257.74M | -$48.14M | -$196.50M |
| EPS Diluted | -$0.46 | -$2.94 | -$0.60 | -$2.50 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 1, 2023 · 32 d after period end
